Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.33 |
| ▸ | DDX3X | O00571 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17324236 | 0.86 | CYP19A1 (0.38) | CYP19A1KEAP1NFE2L2POLBMIF | |
| SCHEMBL21152290 | 0.83 | CYP19A1 (0.39) | CYP19A1POLBMIFMEN1KMT2A | |
| SCHEMBL26501114 | 0.82 | HDAC1 (0.34) | DDX3X | |
| SCHEMBL26501075 | 0.78 | CYP19A1 (0.33) | CYP19A1KEAP1NFE2L2DDX3XPOLB | |
| SCHEMBL18751728 | 0.77 | MMP2 (0.39) | — | |
| SCHEMBL21790525 | 0.77 | CYP19A1 (0.36) | CYP19A1KEAP1NFE2L2 | |
| SCHEMBL16674191 | 0.76 | CYP1A2 (0.41) | CYP19A1POLBALDH1A1 | |
| SCHEMBL14434944 | 0.75 | CYP19A1 (0.42) | CYP19A1POLBALDH1A1 | |
| SCHEMBL18751721 | 0.74 | EPHX2 (0.43) | — | |
| SCHEMBL25974521 | 0.74 | DGAT1 (0.40) | DDX3X |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | KRAS, MDM2, NRAS | CYP19A1 3822/4885KEAP1 132/4885NFE2L2 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.